株探米国株
英語
エドガーで原本を確認する
false 0001174940 0001174940 2024-11-26 2024-11-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934.

 

Date of Report: November 26, 2024

(Date of earliest event reported)

 

Oragenics, Inc.

(Exact name of registrant as specified in its charter)

 

FL   001-32188   59-3410522

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

 

1990 Main Street

Suite 750

Sarasota, FL

  34236
(Address of principal executive offices)   (Zip Code)

 

813-286-7900

(Registrant’s telephone number, including area code)

 

 

(Former Name or Former Address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   OGEN   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 1.02 Termination of Material Definitive Agreement.

 

On November 26, 2024, Oragenics, Inc. (the “Company”) notified its President, J. Michael Redmond (“Executive”), that it was not renewing his Employment Agreement (the “Agreement”) dated December 28, 2023. The initial term of the Agreement is one year. However, pursuant to the Agreement, the initial term automatically renews for one additional year unless either party provides the other party with a notice of non-renewal at least 30 days prior to the expiration of the initial term. Accordingly, as a result of the Company’s non-renewal notice, Executive’s employment under the Agreement will terminate upon the expiration of the initial term. Certain provisions of the Agreement survive the expiration of the Agreement in accordance with the terms of the Agreement.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

No.

 

Description

104   Cover page Interactive Data File (embedded in the cover page formatted in Inline XBRL)

 

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this November 29, 2024.

 

 

ORAGENICS, INC.

(Registrant)

   
  BY: /s/ Janet Huffman
   

Janet Huffman

Chief Financial Officer